Association of probiotic use with nivolumab effectiveness against various cancers: A multicenter retrospective cohort study-Reference-Cited by-同舟云学术

Association of probiotic use with nivolumab effectiveness against various cancers: A multicenter retrospective cohort study

Published:2023-07-08 Issue:16 Volume:12 Page:16876-16880
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Medicine

Author:

Arai Junya¹²^ORCID,Niikura Ryota³,Hayakawa Yoku¹,Suzuki Nobumi¹,Honda Tetsuro⁴,Okamura Takuma⁴,Hasatani Kenkei⁵,Yoshida Naohiro⁶,Nishida Tsutomu⁷^ORCID,Sumiyoshi Tetsuya⁸,Kiyotoki Shu⁹,Ikeya Takashi¹⁰,Arai Masahiro¹¹,Boku Narikazu¹,Fujishiro Mitsuhiro¹

Affiliation:

1. Department of Gastroenterology, Graduate School of Medicine The University of Tokyo Tokyo Japan

2. Department of Gastroenterology The Institute for Medical Science, Asahi Life Foundation Tokyo Japan

3. Gastroenterological Endoscopy Tokyo Medical University Tokyo Japan

4. Department of Gastroenterology Nagasaki Harbor Medical Center Nagasaki Japan

5. Department of Gastroenterology Fukui Prefectural Hospital Fukui Japan

6. Department of Gastroenterology Ishikawa Prefectural Central Hospital Kanazawa‐shi Ishikawa Japan

7. Department of Gastroenterology Toyonaka Municipal Hospital Osaka Japan

8. Department of Gastroenterology Tonan Hospital Sapporo‐shi Hokkaido Japan

9. Department of Gastroenterology Shuto General Hospital Yamaguchi Japan

10. Department of Gastroenterology St. Luke's International Hospital Tokyo Japan

11. Department of Gastroenterology Nerima Hikarigaoka Hospital Tokyo Japan

Abstract

AbstractBackgroundPrevious studies have revealed an association between probiotic use and effectiveness of immune checkpoint inhibitors in renal and lung cancers. However, little is known regarding other cancers, including gastrointestinal cancer.MethodsTo address this issue, we conducted a multicenter retrospective cohort study and the duration of nivolumab treatment for various cancers was compared between probiotic users and non‐users.Results and ConclusionsIn total, 488 patients who received nivolumab therapy were included. In all cancers, no significant differences in treatment duration of nivolumab were observed between probiotic users and non‐users (median 62.0 vs. 56.0, hazard ratio = 1.02, p = 0.825), whereas probiotic use, compared with non‐use, in patients with gastric cancer was significantly associated with a longer duration of nivolumab treatment (55.0 vs. 31.0 days, hazard ratio = 0.69, p = 0.039). In conclusion, probiotics may improve the response to nivolumab and potentially prolong progression‐free survival in patients with gastric cancer.

Funder

Japan Society for the Promotion of Science

Publisher

Wiley

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.6313

Reference18 articles.

1. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy

2. Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors

3. Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients

4. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota

5. Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial